<DOC>
	<DOCNO>NCT00386126</DOCNO>
	<brief_summary>Anemia demonstrate common finding patient heart failure ( HF ) . Previous study hospitalize patient HF find prevalence anemia range 15 % 63 % . More importantly , anemic patient HF increase morbidity mortality . The mechanisms underlying anemia HF multifactorial , involve mild moderate form anemia chronic disease ferropenic anemia . The clinical impact iron supplementation HF patient relatively preserve renal function either chronic disease anemia , ferropenic anemia remain largely unknown . The route iron administration could clinically effective also unclear . Thus , primary aim IRON-HF study ass effect iron supplementation alone ( IV PO ) parameters functional capacity HF patient anemia decreased availability iron .</brief_summary>
	<brief_title>Iron Supplementation Heart Failure Patients With Anemia : The IRON-HF Study</brief_title>
	<detailed_description>The IRON-HF study investigator initiate , multicenter , prospectively design , randomize , double-blind , placebo control clinical trial . Randomization : Each eight participate center randomize patient telephone contact randomization center Hospital de Clínicas de Porto Alegre . The randomization system base computerize table random number perform block three per participate center . Blinding : Each participate center elect third party blind individual ( usually RN ) open allocate medication box , prepare iron sucrose infusion saline administer patient opaque device . Both patient attending physician and/or nurse blind allocate therapy . Oral medication oral placebo identical aspect .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferric oxide , saccharated</mesh_term>
	<criteria>18 year age old ; Outpatients follow HF Clinic tertiary care Hospital clinical diagnosis HF least 3 month study entry ; NYHA functional class II IV , able perform ergospirometry ; Documentation LVEF &lt; 40 % within last 6 month ; Adequate baseline therapy HF base patient ’ functional class ( βblockers , ACE inhibitor irrespective functional class except contraindication , digoxin , spironolactone NYHA class III IV ) ; Stable baseline HF therapy dose medication intent increase dose follow 3 month ; Hemoglobin ≤ 12 g/dl &gt; 9 g/dl ; Transferrin saturation &lt; 20 % ferritin &lt; 500 µg/L ; Ability provide write informed consent . Any clinically overt bleeding : gastrointestinal bleeding , hypermenorrhea , history peptic ulcer without evidence heal inflammatory intestinal disease ; Uncorrected hypothyroidism ; Other inflammatory , neoplastic infectious disease ; Serum creatinine &gt; 1,5 mg/dl ; Previous intolerance oral elemental iron compound ; HF due alcoholic cardiomyopathy , current regular drinker alcoholic beverage HF due peripartum cardiomyopathy ; Recent admission decompensated HF ( last month ) Recent myocardial revascularization procedure ( last 3 month ) ; Recent ACS , stroke TIA ( last 3 month ) ; Active metastatic neoplastic disease life expectancy less year ; Patients heart transplantation list ; Patients participate clinical trial study within last month ; Pregnant lactate woman ; Premenopausal woman use effective method contraception ; Patients use prohibited medication yet accomplish washout period ; Patients currently participate cardiovascular rehabilitation program .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2006</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Anemia</keyword>
	<keyword>Treatment</keyword>
</DOC>